Serum -Klotho and fibroblast growth factor 23 levels are not associated with non-proliferative diabetic retinopathy in type 1 diabetes mellitus

Diabetic retinopathy is a commonly observed cause of blindness and is a common problem in individuals with diabetes. Recent investigations have showed the capability of serum alpha-Klotho and FGF 23 in mitigating the effects of diabetic retinopathy. This study aimed to discover the correlation between FGF 23, alpha-Klotho, and diabetic retinopathy in type 1 diabetics. This case-control study included 63 diabetic patients and 66 healthy controls. Following an overnight duration of fasting, morning blood samples were taken from both the patient and the control groups. The serum concentrations of alpha-Klotho and FGF 23 were quantified. An experienced ophthalmologist inspected the retinopathy. All participants in this study have moderate non-proliferative retinopathy. A p value under 0.05 was considered statistically significant. The mean alpha-Klotho level for retinopathic diabetic patients was 501.7 +/- 172.2 pg/mL and 579.6 +/- 312.1 pg/mL for non-retinopathic diabetic patients. In comparison, alpha-Klotho level of the control group was 523.2 +/- 265.4 pg/mL (p = 0.531). The mean of FGF 23 level did not demonstrate a significant difference (p = 0.259). The mean FGF 23 level were 75.7 +/- 14.0 pg/mL, 74.0 +/- 14.8 pg/mL and 79.3 +/- 14.4 pg/mL in groups, respectively. In conclusion, there was no significant difference in FGF 23 and alpha-Klotho levels between type 1 diabetics with and without retinopathy when compared to the control group.